Seattle Genetics begins Phase I trial of lymphoma and carcinoma drug SGN-CD70A
Seattle Genetics has initiated a Phase I clinical trial assessing SGN-CD70A for CD70-positive relapsed or refractory non-Hodgkin lymphoma (NHL) and metastatic renal cell carcinoma (RCC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Genetics | Kidney Cancer | Lymphoma | Non-Hodgkin's Lymphoma | Pharmaceuticals | Renal Cell Carcinoma